Previous 10 | Next 10 |
Goldman Sachs has launched its coverage on Organon (NYSE:OGN), arguing, among other things, that the market hasn’t adequately appreciated the Women's Health (WH) business of the Merck (MRK) spinoff. The price target set to $40 per share implies a premium of ~26% to the last close. The ...
The European Union drug regulator's Committee for Medicinal Products for Human Use recommended extending the indication for Organon's (NYSE:OGN) fertility treatment, Elonva. The drug regulator said Elonva is indicated for the treatment of adolescent males, that are 14 years and older, w...
Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website at https://www.organon.c...
Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...
Fundamental Diagnosis is an individual investor and former sell-side analyst in healthcare at several top investment banks. The risks of relying too much on the narrative for a stock, how a competitive analysis can serve as a source of idea gen and using a company’s investor pr...
An estimated 21 million American women experience BV Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced they have entered into an agreement whereby Orga...
Three months into 2022, the markets are in turmoil, and highly priced stocks are falling fast. Investors can look for safety in value-oriented investments that are less vulnerable to sharp declines. The businesses listed here are all profitable and trading at incredibly cheap future earning...
MRK and MO might not seem like they go together too well, but the actual underlying business is what matters for an income investor. MRK has a steady business in the healthcare space, and MO has pricing power. They might originate from two different sectors and be quite opposites,...
SCHD's index both rebalances and reconstitutes its holdings the second Friday in March. SCHD has been adjusting to the recent reconstitution. It added 14 stocks. We look at EOG resources which was the largest new holding and at the sectors represented by the rest of the much smaller s...
Ireland-based self-care company, Perrigo Company (NYSE:PRGO), announced on Thursday that the U.S. Food and Drug Administration (FDA) granted the final approval for over-the-counter use of Nasonex 24HR Allergy. Perrigo (PRGO) identified the approval as its “first branded Rx-to-OTC switc...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...